CR20120303A - Tratamientos para trastornos gastrointestinales - Google Patents

Tratamientos para trastornos gastrointestinales

Info

Publication number
CR20120303A
CR20120303A CR20120303A CR20120303A CR20120303A CR 20120303 A CR20120303 A CR 20120303A CR 20120303 A CR20120303 A CR 20120303A CR 20120303 A CR20120303 A CR 20120303A CR 20120303 A CR20120303 A CR 20120303A
Authority
CR
Costa Rica
Prior art keywords
treatments
gastrointestinal disorders
gastrointestinal
useful
treatment
Prior art date
Application number
CR20120303A
Other languages
English (en)
Inventor
G Currie Mark
Fretzen Angelika
Kessler Marco
P Zimmer Daniel
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43503086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120303(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of CR20120303A publication Critical patent/CR20120303A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)

Abstract

La presente invención proporciona péptidos que son útiles para el tratamiento de trastorno gastrointestinales.
CR20120303A 2009-11-09 2012-06-06 Tratamientos para trastornos gastrointestinales CR20120303A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25926409P 2009-11-09 2009-11-09

Publications (1)

Publication Number Publication Date
CR20120303A true CR20120303A (es) 2012-08-08

Family

ID=43503086

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120303A CR20120303A (es) 2009-11-09 2012-06-06 Tratamientos para trastornos gastrointestinales

Country Status (25)

Country Link
US (3) US20140179607A9 (es)
EP (1) EP2499154B1 (es)
JP (1) JP5913115B2 (es)
KR (1) KR20120115495A (es)
CN (1) CN102812038B (es)
AR (1) AR078950A1 (es)
AU (1) AU2010314866B2 (es)
BR (1) BR112012011730A2 (es)
CA (1) CA2779482A1 (es)
CL (1) CL2012001186A1 (es)
CO (1) CO6551683A2 (es)
CR (1) CR20120303A (es)
EA (1) EA022817B1 (es)
EC (1) ECSP12011962A (es)
ES (1) ES2620153T3 (es)
GE (1) GEP20166435B (es)
IL (1) IL219596A0 (es)
MX (2) MX350046B (es)
NZ (1) NZ599751A (es)
SG (1) SG10201407403UA (es)
TW (1) TWI482626B (es)
UA (1) UA114274C2 (es)
UY (2) UY33017A (es)
WO (1) WO2011057272A1 (es)
ZA (1) ZA201203342B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US20120028897A1 (en) * 2008-12-02 2012-02-02 Currie Mark G Methods and compositions for the treatment of fluid retention disorders
AU2010314866B2 (en) * 2009-11-09 2014-10-30 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
CN102822194B (zh) * 2009-12-07 2016-10-26 硬木药品公司 用于胃肠病症的治疗
WO2012155114A1 (en) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Peptides derived from uroguanylin and their use in gastrointestinal disorders
US20160213739A1 (en) * 2011-05-11 2016-07-28 Ironwood Pharmaceuticals, Inc Treatments for disorders using guanylate cyclase c agonists
US9650417B2 (en) * 2011-05-11 2017-05-16 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9617305B2 (en) 2011-06-08 2017-04-11 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012170766A1 (en) * 2011-06-08 2012-12-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2013025969A1 (en) * 2011-08-17 2013-02-21 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2014088623A1 (en) * 2012-07-12 2014-06-12 Forest Laboratories Holdings Limited Linaclotide compositions
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
NZ717739A (en) 2013-08-09 2023-12-22 Ardelyx Inc Compounds and methods for inhibiting phosphate transport
CA2926685A1 (en) * 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
WO2016015055A1 (en) * 2014-07-25 2016-01-28 Ironwood Pharmaceuticals, Inc. Colon cleansing compositions
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB290795A (en) 1927-04-08 1928-05-24 British Colour Printing Compan Improvements in or relating to advertising or display devices
US5879656A (en) * 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US5601990A (en) * 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
US5962220A (en) * 1993-10-26 1999-10-05 Thomas Jefferson University Compositions that specifically bind to colorectal cells and methods of using the same
US5518888A (en) * 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US6060037A (en) * 1993-10-26 2000-05-09 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
AU2001256315A1 (en) * 2000-04-22 2001-11-07 Ipf Pharmaceuticals Gmbh Use of guanylate cyclase-c (gc-c) agonists as insulinotropic factors for treating diabetes type 2
US7371727B2 (en) * 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) * 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN100589839C (zh) * 2003-01-28 2010-02-17 艾恩伍德医药品股份有限公司 多肽及包含多肽的药物组合物
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2007022531A2 (en) 2005-08-19 2007-02-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2008261102B2 (en) * 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
PE20151205A1 (es) * 2008-08-15 2015-08-31 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para administracion oral
WO2010027405A2 (en) * 2008-09-04 2010-03-11 Ironwood Pharmaceuticals, Inc. Stable solid formulations of gc-c receptor agonist polypeptides suitable for oral administration
AU2010314866B2 (en) * 2009-11-09 2014-10-30 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2011156453A2 (en) 2010-06-09 2011-12-15 Combimab, Inc. Therapeutic peptides

Also Published As

Publication number Publication date
EP2499154A1 (en) 2012-09-19
US20130085107A1 (en) 2013-04-04
US20140179607A9 (en) 2014-06-26
AU2010314866A1 (en) 2012-05-31
US8946158B2 (en) 2015-02-03
BR112012011730A2 (pt) 2016-03-08
MX2012005368A (es) 2012-06-13
UY33018A (es) 2011-01-31
MX350046B (es) 2017-08-24
EA022817B1 (ru) 2016-03-31
CN102812038A (zh) 2012-12-05
CO6551683A2 (es) 2012-10-31
UA114274C2 (uk) 2017-05-25
EA201290322A1 (ru) 2013-01-30
NZ599751A (en) 2014-08-29
SG10201407403UA (en) 2014-12-30
ES2620153T3 (es) 2017-06-27
ZA201203342B (en) 2013-01-30
ECSP12011962A (es) 2012-07-31
CA2779482A1 (en) 2011-05-12
TW201116291A (en) 2011-05-16
GEP20166435B (en) 2016-02-25
WO2011057272A1 (en) 2011-05-12
UY33017A (es) 2011-06-30
JP2013510182A (ja) 2013-03-21
US20110118184A1 (en) 2011-05-19
CN102812038B (zh) 2016-05-18
KR20120115495A (ko) 2012-10-18
CL2012001186A1 (es) 2013-07-12
US20140024593A1 (en) 2014-01-23
US8507447B2 (en) 2013-08-13
EP2499154B1 (en) 2016-12-21
IL219596A0 (en) 2012-06-28
AR078950A1 (es) 2011-12-14
TWI482626B (zh) 2015-05-01
AU2010314866B2 (en) 2014-10-30
JP5913115B2 (ja) 2016-05-11

Similar Documents

Publication Publication Date Title
CR20120303A (es) Tratamientos para trastornos gastrointestinales
CL2017001459A1 (es) Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
CR20110580A (es) Compuestos vinil indazolilo
CR20120202A (es) Métodos y composiciones para tratar cáncer
BR112019012062A2 (pt) tratamento de uma doença do trato gastrointestinal com um inibidor de jak e dispositivos
CO6791571A2 (es) Moduladores de la proteína tirosina quinasa 7 (ptk7) para el tratamiento diagnóstico o profilaxis de trastornos neoplásicos
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
CO7071129A2 (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
EA201490029A1 (ru) Соединения, ингибирующие металлоферменты
MX355543B (es) Macrociclos peptidomiméticos.
MA32938B1 (fr) Composes organiques
ECSP11011541A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CO6801724A2 (es) Composiciones y métodos para el tratamiento de la mielofibrosis
NI201500042A (es) Antiandrógenos para el tratamiento del cáncer de próstata resistente a la castración no metastásico
CR20120035A (es) Terapia combinatoria de un anticuerpo anti-cd20 afucosilado con fludarabina y/o mitoxantrona
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
BR112013006567A2 (pt) métodos e composições para tratamento de câncer de pulmão
CY1120877T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
ES2606627T8 (es) Anticuerpos específicos anti-CD160 para el tratamiento de trastornos oculares basados en la neoangiogénesis
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
DOP2016000142A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
BR112016012067A2 (pt) composto para o tratamento de hipo¬glicemia grave